Valproic acid use during radiation therapy for glioblastoma associated with improved survival

International Journal of Radiation Oncology Biology Physics

Volumn 86, Issue 3, 2013, Pages 504-509

  Barker, Christopher A ^a,b   Bishop, Andrew J ^a   Chang, Maria ^a   Beal, Kathryn ^a   Chan, Timothy A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG THERAPY; RADIATION EFFECTS; RADIOTHERAPY; REGRESSION ANALYSIS; UNMANNED AERIAL VEHICLES (UAV);

ANTIEPILEPTIC DRUGS; CONFIDENCE INTERVAL; HISTONE DEACETYLASES; METHODS AND MATERIALS; MULTIVARIABLE ANALYSIS; PRECLINICAL STUDIES; RADIATION THERAPY ONCOLOGY GROUPS; RECURSIVE PARTITIONING ANALYSIS;

PATIENT TREATMENT;

CARBAMAZEPINE; CARMUSTINE; CISPLATIN; ETIRACETAM; LOMUSTINE; PHENOBARBITAL; PHENYTOIN; PROCARBAZINE; TEMOZOLOMIDE; VALPROIC ACID; VINCRISTINE; ALKYLATING AGENT; ANTICONVULSIVE AGENT; DACARBAZINE; DRUG DERIVATIVE; HISTONE DEACETYLASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FEMALE; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICAL RECORD REVIEW; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE; SEIZURE; YOUNG ADULT; ADOLESCENT; BRAIN TUMOR; METHODOLOGY; MORTALITY; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; FEMALE; GLIOBLASTOMA; HISTONE DEACETYLASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; SEIZURES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VALPROIC ACID; YOUNG ADULT;

MLCS; MLOWN;

EID: 84880598419     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2013.02.012     Document Type: Article

References (21)

1. CBTRUS. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumours Diagnosed in the United States in 2004- 2008 (March 23, 2012 Revision). Hinsdale, IL: Central Brain Tumor Registry of the United States; 2012.
2. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10: 459-466.
3. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-1068.
4. Munshi A, Kurland JF, Nishikawa T, et al. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res 2005;11:4912-4922.
5. Phiel CJ, Zhang F, Huang EY, et al. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001;276:36734-36741.
6. van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 2007;6:421-430.
7. Camphausen K, Cerna D, Scott T, et al. Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer 2005; 114:380-386.
8. Van Nifterik KA, Van den Berg J, Slotman BJ, et al. Valproic acid sensitizes human glioma cells for temozolomide and gamma-radiation. J Neurooncol 2012;107:61-67.
9. Chinnaiyan P, Cerna D, Burgan WE, et al. Postradiation sensitization of the histone deacetylase inhibitor valproic acid. Clin Cancer Res 2008;14:5410-5415.
10. Curran WJ Jr., Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
11. Scott CB, Scarantino C, Urtasun R, et al. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: A report using RTOG 90-06. Int J Radiat Oncol Biol Phys 1998;40:51-55.
12. Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;54:1886-1893.
13. van Breemen MS, Rijsman RM, Taphoorn MJ, et al. Efficacy of antiepileptic drugs in patients with gliomas and seizures. J Neurol 2009; 256:1519-1526.
14. Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: Recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 2006;24:2563-2569.
15. Oberndorfer S, Piribauer M, Marosi C, et al. P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol 2005; 72:255-260.
16. Weller M, Gorlia T, Cairncross JG, et al. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 2011;77:1156-1164.
17. Eyal S, Yagen B, Sobol E, et al. The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia 2004;45:737-744.
18. Tsai H-C, Wei K-C, Tsai C-N, et al. Effect of valproic acid on the outcome of glioblastoma multiforme. B J Neurosurg 2012;26:347-354.
19. Kornguth D, Su J, Li X, et al. Valproic acid shows normal tissue protection in a rat spinal cord model. Int J Radiat Oncol Biol Phys 2008;72:S697-S698.
20. Thotala D, Sweeney K, Leahy K, et al. Valproic Acid enhances radiation therapy by protecting normal hippocampal neurons and sensitizing malignant glioblastoma cells in vivo and in vitro. Int J Radiat Oncol Biol Phys 2011;81:S669.
21. Ruben JD, Dally M, Bailey M, et al. Cerebral radiation necrosis: Incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys 2006;65: 499-508.